Next Phase Newsletter

The investment division of a biotech company is solely dedicated to the identification and success of early-stage, biotech start-ups for the firm’s incubation and investment platforms. The firm’s commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

The firm invests globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. Leveraging the firm’s experience and technical advantages in the field of novel drug R&D, the firm provides both cash and in-kind services (EFS) for their investment. Additionally, based on the need, the firm also offers value-added services in operation and logistic support, BD and Financing assistance, etc. to accelerate the growth of its portfolio companies. The firm can allocate from $500,000 to $5,000,000 of equity capital or convertible notes in seed or Series A.

The firm focuses on novel, preclinical therapeutics and is agnostic to indication, modality and geography. The firm is currently most interested in small molecule first-in-class drugs but is open to considering all drug types. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Diagnostics, Medical Devices, or Healthcare IT companies.

The firm does not have specific requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Europe is actively seeking innovative investment opportunities with high potential for growth. With their latest fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm. With this fund, the firm seeks to make 18-20 investments with initial investment sizes in the range of $3-10M. The firm will focus on companies that are based in USA, Canada, and Western Europe, but may review those from other geographies on a case by case basis.

The firm is most interested in life science companies with a digital component. This includes healthcare IT/digital health, utilization of AI/machine learning for drug discovery, genomics, precision medicine, etc. The firm is open to medical devices or diagnostics that have a digital component. In particular, the firm is most interested in technologies that are dedicated to the treatment of chronic disorders and lead to improved outcomes and lower care costs in hospital systems. The firm will not consider traditional biopharmaceutical modalities.

The firm carefully evaluates investment opportunities based on the quality and experienced of the management team as well as market opportunity. The firm is open to both leading and co-investing, and in the former case will seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm in Japan is currently investing from its second fund which had an initial close in 2020. The firm is actively seeking investment opportunities in Seed to Series A rounds, and can invest up to $3M over the company’s lifecycle. The firm is open to companies based in Japan, USA, and Europe.

The firm is interested in cutting edge technologies in all areas of life sciences, and will consider all opportunities in therapeutics, medical devices, diagnostics, and digital health across all indications. As MIJ is an early-stage investor, the firm will consider any technologies in pre-clinical stage of development.

The firm does not have specific company or management team requirements. The firm can act as either a lead or co-investor, but if the company is very early-stage, the firm will expect to have a more active role in supporting the company’s growth and will seek to act as the lead investor. In addition, the firm has partnered with numerous organizations and has a strong network the firm can leverage to provide operational/commercialization support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm with offices China makes late venture and growth stage investments exclusively in the life sciences and has invested in nearly 50 companies to date. The firm’s target investment size is USD 15-20 million per company and typically USD 5 million for cross-border investments. The firm primarily focuses on opportunities in China; however the firm is also interested in companies abroad that have a strong China angle or China strategy in near term (target market, R&D/manufacturing, sales, etc). The firm is actively seeking new investment opportunities.

The firm seeks to invest in late-stage assets that are on market or close to commercialization. The firm is interested in therapeutics/pharmaceuticals, medical devices, diagnostics, and healthcare services. For therapeutics, the firm will consider small molecules and biologics as well as biosimilars and reformulated drugs. At minimum, the product should be in Phase III of clinical trials. The firm may look at Phase II candidates that have a relatively less complicated clinical trial. For example, the firm will not consider biologics in Phase II. For indications, the firm focuses on products that address a large unmet medical need in China. This includes diabetes, cardiovascular, cerebrovascular, liver, and degenerative diseases. For medical devices, the firm is opportunistic in terms of subsectors. Similar to therapeutics, the firm focuses on indications relevant to China. The firm looks for devices that are very close to market or market approved.

The firm is only interested in companies that have a strong China angle or strategy. The firm typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in Europe invests in healthcare and technology companies, and seeks to partner with awesome entrepreneurs who are transforming healthcare – solving big problems and creating great companies. Typical investment is $200k-1M and the firm seeks to invest globally.

The firm‘s interests include chronic eye diseases, diabetes, Parkinson’s, Alzheimer’s, AI-enabled breast cancer detection, stroke, chronic kidney disease, digital health, medical devices, telemedicine. The firm does not actively review opportunities in therapeutics at this time.

The firm partners with resourceful entrepreneurs who have proven their ability to get results.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A clinical stage biopharmaceutical company with multiple offices in China and USA is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing, and is currently developing nine therapeutic antibody molecules targeting multiple indications. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.

The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage healthcare venture fund established in 2018 with USA-based teams looks to invest in companies and teams with novel approaches in both the life sciences and Bio-IT sector.

The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Bio-IT sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow.

The firm is actively looking for companies from Seed to Series A and is focused on the US with select opportunities globally.

The firm is focused on two main investment themes:

(1) Life Sciences – The firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and immune based disease. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;

(2) Bio IT – Bio IT is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery / development (proteomics and metabolomics), and new solutions to improve the efficiency of new modalities (i.e., cell therapy manufacturing, gene therapy carries, etc.).

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.